06 July 2017 | News
The four parties signed a Letter of Intent (LoI) for Cooperation at the BioTaiwan 2017 BioBusiness Asia Conference.
The Development Center for Biotechnology (DCB), the Medical and Pharmaceutical Industrial Technology Development Center (PITDC), and Taipei Medical University (TMU), three of Taiwan's premier biomedical institutions, have teamed up with Baltimore-based Insilico Medicine to develop groundbreaking research in applied A.I. for biomedical science. The four parties signed a Letter of Intent (LoI) for Cooperation at the BioTaiwan 2017 BioBusiness Asia Conference.
TMU, one of the world's top medical schools and hospital groups, has been a pioneer in adopting state-of-the-art technologies to provide healthcare services, and recently announced the adoption of IBM's Watson Health.
PITDC, Taiwan's leading medical and pharmaceutical research institute also announced its intent to adopt A.I. for drug discovery and development.
Insilico Medicine, a rising star in applying A.I. in healthcare, has recently been identified as one of the top 5 A.I. startups for social impact by Nvidia. The company uses a new deep learning technique known as generative adversarial networks, or GANs.
With over 400 dedicated researchers and state-of-the-art facilities, DCB specializes in developing biologics and small molecule drugs, botanical drugs, as well as technologies required for preclinical testing. Its expertise arises from the integration of a number of diverse disciplines, including biology, chemistry, protein purification and engineering, as well as analytical and quality assurance.